United Therapeutics Corporation To Report Fourth Quarter And Annual 2018 Financial Results Before The Market Opens On Wednesday, February 27, 2019
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and annual 2018 financial results before the market opens on Wednesday, February 27, 2019.
United Therapeutics will host a teleconference on Wednesday, February 27, 2019, at 9:00 a.m. Eastern Time to discuss its fourth quarter and annual 2018 financial results. In addition, R. James White, M.D., Ph.D., Professor of Medicine, Pharmacology & Physiology in the Division of Pulmonary & Critical Care Medicine at the University of Rochester Medical Center and steering committee member for the FREEDOM-EV study of Orenitram®, will be joining the teleconference and will be available to answer questions regarding data from the FREEDOM-EV study.
The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 1-855-859-2056, with international callers dialing 1-404-537-3406, and using access code: 1595239.
This teleconference is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm. [uthr-g]
About United Therapeutics
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment and society – will sustain our success in the long term.
Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.
View original content:SOURCE United Therapeutics Corporation
Company Codes: NASDAQ-NMS:UTHR